TY - JOUR AU - Nuhn, P. AU - Bono, J. S. AU - Fizazi, K. AU - Freedland, S. J. AU - Grilli, M. AU - Kantoff, P. W. PY - 2019 DA - 2019// TI - Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate vancer in the era of precision oncology JO - Eur Urol VL - 75 ID - Nuhn2019 ER - TY - JOUR AU - Cornford, P. AU - Bellmunt, J. AU - Bolla, M. AU - Briers, E. AU - Santis, M. AU - Gross, T. PY - 2017 DA - 2017// TI - EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer JO - Eur Urol VL - 71 ID - Cornford2017 ER - TY - JOUR AU - Barbieri, C. E. AU - Chinnaiyan, A. M. AU - Lerner, S. P. AU - Swanton, C. AU - Rubin, M. A. PY - 2017 DA - 2017// TI - The emergence of precision urologic oncology: a collaborative review on biomarker-driven therapeutics JO - Eur Urol VL - 71 ID - Barbieri2017 ER - TY - JOUR AU - Tan, D. S. W. AU - Thomas, G. V. AU - Garrett, M. D. AU - Banerji, U. AU - Bono, J. S. AU - Kaye, S. B. PY - 2009 DA - 2009// TI - Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development JO - Cancer J VL - 15 ID - Tan2009 ER - TY - JOUR AU - Simon, R. PY - 2014 DA - 2014// TI - Biomarker based clinical trial design JO - Chin Clin Oncol VL - 3 ID - Simon2014 ER - TY - JOUR AU - Berry, S. M. AU - Connor, J. T. AU - Lewis, R. J. PY - 2015 DA - 2015// TI - The platform trial: an efficient strategy for evaluating multiple treatments JO - JAMA. VL - 313 ID - Berry2015 ER - TY - JOUR AU - Berry, D. A. PY - 2012 DA - 2012// TI - Adaptive clinical trials in oncology JO - Nat Rev Clin Oncol VL - 9 ID - Berry2012 ER - TY - STD TI - Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38-52. ID - ref8 ER - TY - JOUR AU - Scher, H. I. AU - Sawyers, C. L. PY - 2005 DA - 2005// TI - Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis JO - J Clin Oncol VL - 23 ID - Scher2005 ER - TY - STD TI - Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015; [cited 2019 Apr 12]; Available from: https://www.auajournals.org/doi/abs/10.1016/j.juro.2015.06.106. UR - https://www.auajournals.org/doi/abs/10.1016/j.juro.2015.06.106 ID - ref10 ER - TY - JOUR AU - Spritzer, C. E. AU - Afonso, P. D. AU - Vinson, E. N. AU - Turnbull, J. D. AU - Morris, K. K. AU - Foye, A. PY - 2013 DA - 2013// TI - Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success JO - Radiology. VL - 269 ID - Spritzer2013 ER - TY - STD TI - Bova GS, Kallio HML, Annala M, Kivinummi K, Högnäs G, Häyrynen S, et al. Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. Cold Spring Harb Mol Case Stud. 2016;2(3):78–86. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853517/. [cited 2019 Jul 22]. UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853517/ ID - ref12 ER - TY - JOUR AU - Gundem, G. AU - Loo, P. AU - Kremeyer, B. AU - Alexandrov, L. B. AU - Tubio, J. M. C. AU - Papaemmanuil, E. PY - 2015 DA - 2015// TI - The evolutionary history of lethal metastatic prostate cancer JO - Nature. VL - 520 ID - Gundem2015 ER - TY - JOUR AU - Siravegna, G. AU - Marsoni, S. AU - Siena, S. AU - Bardelli, A. PY - 2017 DA - 2017// TI - Integrating liquid biopsies into the management of cancer JO - Nat Rev Clin Oncol VL - 14 ID - Siravegna2017 ER - TY - JOUR AU - Wan, J. C. M. AU - Massie, C. AU - Garcia-Corbacho, J. AU - Mouliere, F. AU - Brenton, J. D. AU - Caldas, C. PY - 2017 DA - 2017// TI - Liquid biopsies come of age: towards implementation of circulating tumour DNA JO - Nat Rev Cancer VL - 17 ID - Wan2017 ER - TY - STD TI - Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst. 2017;109(12):78–86. ID - ref16 ER - TY - JOUR AU - Romanel, A. AU - Tandefelt, D. G. AU - Conteduca, V. AU - Jayaram, A. AU - Casiraghi, N. AU - Wetterskog, D. PY - 2015 DA - 2015// TI - Plasma AR and abiraterone-resistant prostate cancer JO - Sci Transl Med VL - 7 ID - Romanel2015 ER - TY - JOUR AU - Goodall, J. AU - Mateo, J. AU - Yuan, W. AU - Mossop, H. AU - Porta, N. AU - Miranda, S. PY - 2017 DA - 2017// TI - Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition JO - Cancer Discov VL - 7 ID - Goodall2017 ER - TY - JOUR AU - Frenel, J. S. AU - Carreira, S. AU - Goodall, J. AU - Roda, D. AU - Perez-Lopez, R. AU - Tunariu, N. PY - 2015 DA - 2015// TI - Serial next generation sequencing of circulating cell free DNA evaluating tumour clone response to molecularly targeted drug administration JO - Clin Cancer Res VL - 21 ID - Frenel2015 ER - TY - JOUR AU - Terada, N. AU - Akamatsu, S. AU - Kobayashi, T. AU - Inoue, T. AU - Ogawa, O. AU - Antonarakis, E. S. PY - 2017 DA - 2017// TI - Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications JO - Ther Adv Med Oncol VL - 9 ID - Terada2017 ER - TY - STD TI - Prostate Cancer Biomarker Enrichment and Treatment Selection - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Oct 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03385655. UR - https://clinicaltrials.gov/ct2/show/NCT03385655 ID - ref21 ER - TY - JOUR AU - Berry, D. A. PY - 2015 DA - 2015// TI - The Brave New World of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research JO - Mol Oncol VL - 9 ID - Berry2015 ER - TY - JOUR AU - Kaplan, R. AU - Maughan, T. AU - Crook, A. AU - Fisher, D. AU - Wilson, R. AU - Brown, L. PY - 2013 DA - 2013// TI - Evaluating many treatments and biomarkers in oncology: a new design JO - J Clin Oncol VL - 31 ID - Kaplan2013 ER - TY - JOUR AU - Saville, B. R. AU - Berry, S. M. PY - 2016 DA - 2016// TI - Efficiencies of platform clinical trials: a vision of the future JO - Clinical Trials VL - 13 ID - Saville2016 ER - TY - JOUR AU - Berry, D. A. PY - 2006 DA - 2006// TI - Bayesian clinical trials JO - Nat Rev Drug Discov VL - 5 ID - Berry2006 ER - TY - STD TI - Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, et al. Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations. JCO Precision Oncol. 2020;16 [cited 2020 May 12]; Available from: https://ascopubs.org/doi/pdf/10.1200/PO.19.00346. UR - https://ascopubs.org/doi/pdf/10.1200/PO.19.00346 ID - ref26 ER - TY - JOUR AU - Mayrhofer, M. AU - Laere, B. AU - Whitington, T. AU - Oyen, P. AU - Ghysel, C. AU - Ampe, J. PY - 2018 DA - 2018// TI - Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis JO - Genome Med VL - 21 ID - Mayrhofer2018 ER - TY - JOUR AU - Laere, B. AU - Oeyen, S. AU - Mayrhofer, M. AU - Whitington, T. AU - Dam, P. -. J. AU - Oyen, P. PY - 2019 DA - 2019// TI - TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer JO - Clin Cancer Res VL - 25 ID - Laere2019 ER - TY - JOUR AU - Robinson, D. AU - Allen, E. M. AU - Wu, Y. -. M. AU - Schultz, N. AU - Lonigro, R. J. AU - Mosquera, J. -. M. PY - 2015 DA - 2015// TI - Integrative clinical genomics of advanced prostate cancer JO - Cell. VL - 162 ID - Robinson2015 ER - TY - JOUR AU - Haffner, M. C. AU - Mosbruger, T. AU - Esopi, D. M. AU - Fedor, H. AU - Heaphy, C. M. AU - Walker, D. A. PY - 2013 DA - 2013// TI - Tracking the clonal origin of lethal prostate cancer JO - J Clin Invest VL - 123 ID - Haffner2013 ER - TY - JOUR AU - Antonarakis, E. S. AU - Lu, C. AU - Wang, H. AU - Luber, B. AU - Nakazawa, M. AU - Roeser, J. C. PY - 2014 DA - 2014// TI - AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer JO - N Engl J Med VL - 371 ID - Antonarakis2014 ER - TY - JOUR AU - Armstrong, A. J. AU - Halabi, S. AU - Luo, J. AU - Nanus, D. M. AU - Giannakakou, P. AU - Szmulewitz, R. Z. PY - 2019 DA - 2019// TI - Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study JO - JCO. VL - 37 ID - Armstrong2019 ER - TY - JOUR AU - Plymate, S. R. AU - Sharp, A. AU - Bono, J. S. PY - 2018 DA - 2018// TI - Nuclear circulating tumor cell androgen receptor variant 7 in castration-resistant prostate cancer: the devil is in the detail JO - JAMA Oncol VL - 4 ID - Plymate2018 ER - TY - JOUR AU - Bernemann, C. AU - Schnoeller, T. J. AU - Luedeke, M. AU - Steinestel, K. AU - Boegemann, M. AU - Schrader, A. J. PY - 2017 DA - 2017// TI - Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer JO - Eur Urol VL - 71 ID - Bernemann2017 ER - TY - JOUR AU - Antonarakis, E. S. AU - Lu, C. AU - Luber, B. AU - Wang, H. AU - Chen, Y. AU - Zhu, Y. PY - 2017 DA - 2017// TI - Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide JO - J Clin Oncol VL - 35 ID - Antonarakis2017 ER - TY - JOUR AU - Mateo, J. AU - Carreira, S. AU - Sandhu, S. AU - Miranda, S. AU - Mossop, H. AU - Perez-Lopez, R. PY - 2015 DA - 2015// TI - DNA-repair defects and olaparib in metastatic prostate cancer JO - N Engl J Med VL - 373 ID - Mateo2015 ER - TY - JOUR AU - Pomerantz, M. M. AU - Spisák, S. AU - Jia, L. AU - Cronin, A. M. AU - Csabai, I. AU - Ledet, E. PY - 2017 DA - 2017// TI - The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer JO - Cancer. VL - 123 ID - Pomerantz2017 ER - TY - JOUR AU - Cheng, H. H. AU - Pritchard, C. C. AU - Boyd, T. AU - Nelson, P. S. AU - Montgomery, B. PY - 2016 DA - 2016// TI - Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer JO - Eur Urol VL - 69 ID - Cheng2016 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 ID - Le2015 ER - TY - JOUR AU - Le, D. T. AU - Durham, J. N. AU - Smith, K. N. AU - Wang, H. AU - Bartlett, B. R. AU - Aulakh, L. K. PY - 2017 DA - 2017// TI - Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade JO - Science VL - 357 ID - Le2017 ER - TY - JOUR AU - Robinson, D. R. AU - Wu, Y. -. M. AU - Lonigro, R. J. AU - Vats, P. AU - Cobain, E. AU - Everett, J. PY - 2017 DA - 2017// TI - Integrative clinical genomics of metastatic cancer JO - Nature. VL - 548 ID - Robinson2017 ER - TY - JOUR AU - Cabel, L. AU - Loir, E. AU - Gravis, G. AU - Lavaud, P. AU - Massard, C. AU - Albiges, L. PY - 2017 DA - 2017// TI - Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients JO - J Immunother Cancer VL - 18 ID - Cabel2017 ER - TY - JOUR AU - Zehir, A. AU - Benayed, R. AU - Shah, R. H. AU - Syed, A. AU - Middha, S. AU - Kim, H. R. PY - 2017 DA - 2017// TI - Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients JO - Nat Med VL - 23 ID - Zehir2017 ER - TY - JOUR AU - Abida, W. AU - Cheng, M. L. AU - Armenia, J. AU - Middha, S. AU - Autio, K. A. AU - Vargas, H. A. PY - 2019 DA - 2019// TI - Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade JO - JAMA Oncol. VL - 5 ID - Abida2019 ER - TY - STD TI - Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry CD, Annala M, Aprikian A, Armenia J, Arora A, Auman JT. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25. ID - ref45 ER - TY - JOUR AU - Rajpar, S. AU - Carmel, A. AU - Merabet, Z. AU - Vielh, P. AU - Foulon, S. AU - Lesaunier, F. PY - 2017 DA - 2017// TI - The benefit of combining docetaxel to androgen deprivation therapy in localized and metastatic castration-sensitive prostate cancer as predicted by ERG status: An analysis of two GETUG phase III trials JO - JCO VL - 35 ID - Rajpar2017 ER - TY - STD TI - Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precision Oncol. 2019;10 [cited 2019 Sep 17]; Available from: https://ascopubs.org/doi/pdf/10.1200/PO.18.00283. UR - https://ascopubs.org/doi/pdf/10.1200/PO.18.00283 ID - ref47 ER - TY - JOUR AU - Barker, A. D. AU - Sigman, C. C. AU - Kelloff, G. J. AU - Hylton, N. M. AU - Berry, D. A. AU - Esserman, L. J. PY - 2009 DA - 2009// TI - I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy JO - Clin Pharmacol Ther VL - 86 ID - Barker2009 ER - TY - JOUR AU - Annala, M. AU - Vandekerkhove, G. AU - Khalaf, D. AU - Taavitsainen, S. AU - Beja, K. AU - Warner, E. W. PY - 2018 DA - 2018// TI - Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer JO - Cancer Discov. VL - 8 ID - Annala2018 ER - TY - JOUR AU - Scher, H. I. AU - Morris, M. J. AU - Stadler, W. M. AU - Higano, C. AU - Basch, E. AU - Fizazi, K. PY - 2016 DA - 2016// TI - Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3 JO - J Clin Oncol VL - 34 ID - Scher2016 ER - TY - JOUR AU - Korn, E. L. AU - Freidlin, B. PY - 2011 DA - 2011// TI - Outcome-adaptive randomization: is it useful? JO - J Clin Oncol VL - 29 ID - Korn2011 ER - TY - JOUR AU - Wathen, J. K. AU - Thall, P. F. PY - 2017 DA - 2017// TI - A simulation study of outcome adaptive randomization in multi-arm clinical trials JO - Clin Trials VL - 14 ID - Wathen2017 ER - TY - JOUR AU - Buyse, M. AU - Saad, E. D. AU - Burzykowski, T. PY - 2016 DA - 2016// TI - Adaptive randomization of neratinib in early breast cancer JO - N Engl J Med VL - 375 ID - Buyse2016 ER - TY - JOUR AU - Viele, K. AU - Broglio, K. AU - McGlothlin, A. AU - Saville, B. R. PY - 2020 DA - 2020// TI - Comparison of methods for control allocation in multiple arm studies using response adaptive randomization JO - Clin Trials. VL - 17 ID - Viele2020 ER - TY - JOUR AU - Wason, J. M. S. AU - Trippa, L. PY - 2014 DA - 2014// TI - A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials JO - Stat Med VL - 33 ID - Wason2014 ER - TY - JOUR AU - Trippa, L. AU - Lee, E. Q. AU - Wen, P. Y. AU - Batchelor, T. T. AU - Cloughesy, T. AU - Parmigiani, G. PY - 2012 DA - 2012// TI - Bayesian adaptive randomized trial design for patients with recurrent glioblastoma JO - J Clin Oncol VL - 30 ID - Trippa2012 ER - TY - JOUR AU - Harrington, D. AU - Parmigiani, G. PY - 2016 DA - 2016// TI - Adaptive randomization of neratinib in early breast cancer JO - N Engl J Med VL - 375 ID - Harrington2016 ER - TY - JOUR AU - London, A. J. PY - 2018 DA - 2018// TI - Learning health systems, clinical equipoise and the ethics of response adaptive randomisation JO - J Med Ethics VL - 44 ID - London2018 ER -